Literature DB >> 33917394

Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies.

Hellen Kuasne1,2, Luisa Matos do Canto1, Mads Malik Aagaard1, Juan Jose Moyano Muñoz2, Camille De Jamblinne3, Fabio Albuquerque Marchi2, Cristovam Scapulatempo-Neto4,5, Eliney Ferreira Faria4,6, Ademar Lopes7, Sébastien Carréno3, Silvia Regina Rogatto1.   

Abstract

Penile cancer (PeCa) is a common disease in poor and developing countries, showing high morbidity rates. Despite the recent progress in understanding the molecular events involved in PeCa, the lack of well-characterized in vitro models precludes new advances in anticancer drug development. Here we describe the establishment of five human primary penile cancer-derived cell cultures, including two epithelial and three cancer-associated fibroblast (CAF) cells. Using high-throughput genomic approaches, we found that the epithelial PeCa derived- cells recapitulate the molecular alterations of their primary tumors and present the same deregulated signaling pathways. The differentially expressed genes and proteins identified are components of key oncogenic pathways, including EGFR and PI3K/AKT/mTOR. We showed that epithelial PeCa derived cells presented a good response to cisplatin, a common therapeutic approach used in PeCa patients. The growth of a PeCa-derived cell overexpressing EGFR was inhibited by EGFR inhibitors (cetuximab, gefitinib, and erlotinib). We also identified CAF signature markers in three PeCa-derived cells with fibroblast-like morphology, indicating that those cells are suitable models for PeCa microenvironment studies. We thus demonstrate the utility of PeCa cell models to dissect mechanisms that promote penile carcinogenesis, which are useful models to evaluate therapeutic approaches for the disease.

Entities:  

Keywords:  CAFs; EGFR inhibitors; cancer cell models; genomic profile; penile cancer; protein expression; translatomic profile

Year:  2021        PMID: 33917394     DOI: 10.3390/cells10040814

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  2 in total

1.  Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.

Authors:  Xuemin Lu; Xin Lu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2022-02-25       Impact factor: 11.414

2.  Interplay Between Immune and Cancer-Associated Fibroblasts: A Path to Target Metalloproteinases in Penile Cancer.

Authors:  Sarah Santiloni Cury; Hellen Kuasne; Jeferson Dos Santos Souza; Juan Jose Moyano Muñoz; Jeyson Pereira da Silva; Ademar Lopes; Cristovam Scapulatempo-Neto; Eliney Ferreira Faria; Jean-Marie Delaissé; Fabio Albuquerque Marchi; Silvia Regina Rogatto
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.